MiNK Therapeutics Faces Nasdaq Delisting Warning
Ticker: INKT · Form: 8-K · Filed: Aug 30, 2024 · CIK: 1840229
Sentiment: bearish
Topics: delisting, compliance, stock-price
TL;DR
Nasdaq says MiNK's stock price is too low, might get kicked off.
AI Summary
MiNK Therapeutics, Inc. announced on August 27, 2024, that it received a notification from the Nasdaq Stock Market indicating non-compliance with listing rules. The company was not in compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market, as its closing bid price had fallen below $1.00 per share for 30 consecutive business days.
Why It Matters
This notification signals potential delisting from Nasdaq, which could significantly impact the company's liquidity, investor confidence, and ability to raise capital.
Risk Assessment
Risk Level: high — The company is at high risk of delisting from a major stock exchange due to failure to meet minimum bid price requirements.
Key Numbers
- 30 — consecutive business days (Period the stock price remained below $1.00)
Key Players & Entities
- MiNK Therapeutics, Inc. (company) — Registrant
- Nasdaq Stock Market (company) — Exchange issuing notification
- The Nasdaq Capital Market (company) — Specific market within Nasdaq
- $1.00 (dollar_amount) — Minimum bid price requirement
FAQ
What specific listing rule did MiNK Therapeutics violate?
MiNK Therapeutics violated the minimum bid price requirement for continued listing on The Nasdaq Capital Market, as its closing bid price was below $1.00 per share for 30 consecutive business days.
What is the date of the notification from Nasdaq?
The notification from Nasdaq was received on August 27, 2024.
What is the consequence of failing to meet the minimum bid price requirement?
The consequence is non-compliance with Nasdaq's listing rules, leading to a potential delisting from The Nasdaq Capital Market.
What is the company's plan to regain compliance?
The filing does not specify the company's plan to regain compliance, only that it received the notification.
What was the former name of MiNK Therapeutics?
The former name of MiNK Therapeutics was AgenTus Therapeutics, Inc.
Filing Stats: 618 words · 2 min read · ~2 pages · Grade level 12.2 · Accepted 2024-08-30 16:05:08
Key Financial Figures
- $0.00001 — ch registered Common Stock, par value $0.00001 per share INKT The Nasdaq Stock Mar
- $1.00 — Company's common stock had closed below $1.00 per share for the previous 30 consecuti
Filing Documents
- inkt-20240827.htm (8-K) — 36KB
- 0000950170-24-102321.txt ( ) — 150KB
- inkt-20240827.xsd (EX-101.SCH) — 25KB
- inkt-20240827_htm.xml (XML) — 5KB
01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously disclosed on February 29, 2024 in the Current Report on Form 8-K filed by MiNK Therapeutics, Inc. (the "Company"), on February 26, 2024, the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notified the Company that the bid price for the Company's common stock had closed below $1.00 per share for the previous 30 consecutive trading days and, in accordance with the Nasdaq Listing Rules, the Company was provided a 180-calendar day grace period to regain compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the "Bid Price Rule"), through August 26, 2024. While the Company's common stock traded above $1.00 per share on several occasions during the grace period, on August 27, 2024, the Company received formal notice from Nasdaq stating the Company was unable to regain compliance with the Minimum Bid Price Requirement. Consequently, the Company's common stock is now subject to potential delisting from Nasdaq unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the "Panel"). The Company intends to request a hearing, which will stay any further action by Nasdaq and the Company's common stock will continue to be eligible to trade on The Nasdaq Capital Market at least pending the conclusion of the hearing process. There can be no assurance that the Panel will determine to continue the Company's listing or that the Company will be able to demonstrate compliance with the applicable listing criteria within the period of time that may be granted by the Panel.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MiNK Therapeutics, Inc. Date: August 30, 2024 By: /s/ Jennifer Buell, Ph.D. Jennifer Buell, Ph.D., CEO